Published: 20th Dec 2024
By: Value Research
Senores Pharmaceuticals primarily manufactures off-patent generic products and operates two manufacturing facilities in the US and India (Ahmedabad). It operates in over 45 countries and has partnered with well-established brands like Sun Pharma, Dr Reddys and Alkem Laboratories to sell its products.
EBIT is earnings before interest and taxes PAT is profit after tax TTM (trailing twelve months) is as of September 2024
ROE is return on equity ROCE is return on capital employed TTM is as of September 2024
Senores Pharmaceuticals boasts long-term sales partnerships with industry titans like Sun Pharma, Alkem, Jubilant, etc., and manufacturing for big names in the US. This can help the company establish a significant presence across markets.
Between FY22 and FY24, Senores Pharmaceuticals reported negative cash flow from operations. This was primarily due to higher working capital requirements as the company’s operations scaled up significantly post the acquisition of Havix and Ratnatris.
Senores Pharmaceuticals’ US-based facility came under scrutiny from the US FDA in 2022, which cleared recently. Such regulatory actions can significantly impact its financials.